Delivery Order SPE2DB20D1004-SPE2DB25FNKMG
- Not listed
- The Defense Logistics Agency awarded a $6,285.41 firm fixed price delivery order to AmerisourceBergen Drug Corp for OmniPod 5 Dexcom G7 Generation 5 insulin infusion pods on September 2, 2025. This is a non-set-aside competitive award with an ultimate completion date of September 3, 2025, and performance will occur at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for OmniPod 5 Dexcom G7 Generation 5 insulin delivery pods valued at $4,737.07. The non-competitive delivery order, issued on July 31, 2025, with an ultimate completion date of August 1, 2025, represents a small-value transaction for specialized diabetes management medical devices. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and healthcare solutions...
- The Defense Logistics Agency awarded a delivery order valued at $1,193.52 to AmerisourceBergen Drug Corp on June 3, 2025, for OmniPod 5 Dexcom G7 Generation 5 insulin delivery pods. This competitive award, with no set-aside designation, was issued under firm fixed pricing and is scheduled for completion by June 4, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a child contract, this delivery order is supported by...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $9,960.07 to AmerisourceBergen Drug Corp for OmniPod 5 Dexcom G7 Generation 5 insulin infusion pods. The contract, awarded on April 24, 2025, with a completion date of April 25, 2025, represents a firm fixed-price, non-set-aside procurement executed under AmerisourceBergen's existing DLA Troop Support Medical Indefinite Delivery Contract (IDC). The performance location is listed as AmerisourceBergen's corporate headquarters in...
- The Defense Logistics Agency awarded a $2,395.34 delivery order to AmerisourceBergen Drug Corp for OmniPod 5 Dexcom G7 Generation 5 insulin infusion pods. The contract, issued on July 25, 2025, with an ultimate completion date of July 28, 2025, represents a firm fixed price procurement with no set-aside designation. AmerisourceBergen's corporate office in Conshohocken, Pennsylvania serves as the place of performance for this medical device delivery, which supports the federal government's...
- The Defense Logistics Agency awarded a $50,317.84 firm fixed-price delivery order to AmerisourceBergen Drug Corp for OmniPod 5 Dexcom G7 generation 5 insulin infusion pods. The contract, issued on August 26, 2025, with completion by August 27, 2025, represents a non-competitive delivery order without set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform this work at its corporate office location. This delivery order falls under the company's...
- The Defense Logistics Agency awarded a $24,265.08 delivery order to AmerisourceBergen Drug Corp on June 18, 2025, for the supply of OmniPod 5 Dexcom G7 Generation 5 insulin infusion pods. The contract represents a firm fixed-price delivery order with an ultimate completion date of June 20, 2025, and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. This award was not designated as a set-aside contract, indicating it was competitively awarded through open...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for OmniPod 5 Dexcom G7 Gen 5 insulin infusion pods valued at $1,222.32. This competitive, firm fixed-price delivery order was issued on August 7, 2025, with an ultimate completion date of August 8, 2025, and is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a continuation of AmerisourceBergen's role as a critical pharmaceutical and medical...
- The Defense Logistics Agency awarded a $16,496.42 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for OmniPod 5 Dexcom G7 Generation 5 insulin infusion pods. The contract, which is a non-set-aside award, represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 prime vendor agreement running through December 2026. Performance will be completed by September 11,...
- The Defense Logistics Agency awarded a delivery order valued at $1,833.48 to AmerisourceBergen Drug Corp for OmniPod 5 Dexcom G7 Generation 5 insulin delivery pods. The award, issued on July 28, 2025, with an ultimate completion date of July 29, 2025, utilizes firm fixed price pricing and represents a non-set-aside competitive procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor for federal medical supply...
- SPE2DB20D1004Indefinite Delivery Contract
- SPE2DB20D1004-SPE2DB25FNKMGDelivery Order
The Defense Logistics Agency awarded a $1,833.48 firm fixed price delivery order to AmerisourceBergen Drug Corp for OmniPod 5 Dexcom G7 Generation 5 insulin infusion pods on September 3, 2025, with a completion date of September 4, 2025. The award is unclassified with no set-aside designation and represents a competitive procurement. AmerisourceBergen Drug Corp, a major pharmaceutical and medical device distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order is issued under AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare systems. The IDC encompasses a broad range of pharmaceutical products and medical supplies across multiple therapeutic domains, enabling AmerisourceBergen to supply critical medical commodities to the Defense Health Agency, U.S. Coast Guard, and other federal healthcare customers worldwide. This specific delivery order for diabetes management devices aligns with the DLA's strategic approach to establish multiple Pharmaceutical Prime Vendor Global Program Generation V contracts across separate regions. The award reinforces AmerisourceBergen's established capability in fulfilling federal medical procurement requirements through open competition, reflecting its role as a critical vendor within the federal medical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.8k | 9/3/25 |